Metabolic Syndromes (MetS) are recognized as a cluster of risk factors
which are known to increase the likelihood of obesity, type 2 diabetes (T2D) and
cardiovascular disorders (CVDs). It is significant to understand disease pathology in
order to discover a pathological mechanism leading to the development of MetS.
Elevated triglycerides, increased blood pressure, hyperglycemia (increased blood
glucose levels), low levels of High-density lipoprotein (HDL) cholesterol and elevated
waist circumference are key parameters in diagnosing MetS. Various therapeutic
interventions have been developed for treating metabolic diseases like polypills which
are commonly known as combination pills, along with the fixed dose combinations. In
addition to pharmacological handling, surgical treatment is also showing success in
treating MetS such as Bariatric treatment. With the emerging experimental techniques,
gene therapy allows the replacement of a defective gene with a healthy one, which may
eventually reverse the disease. Leptin Gene Therapy, ZFN Gene Editing, CRISPR/
Cas9 genome editing are different platforms of gene therapy which are showing
promising results in treating the metabolic disease. Novel experimental approaches and
pharmacological treatments can provide a better insight into metabolic syndrome and
its related complications, thereby reducing its global burden.
Keywords: CRISPR/Cas9 genome editing, CVDs, Metabolic Syndrome, Obesity, Polypills, Type 2 Diabetes.